Skip to content
Company Analysis

Hong Kong Pharma Digital Technology Holdings Ltd HKPD

A comprehensive view of key metrics, scores, and financial health for Hong Kong Pharma Digital Technology Holdings Ltd

Overview of Cellyan Biotechnology Co., Ltd

HKPD NCM
Healthcare Pharmaceutical Retailers Micro Cap
Cellyan Biotechnology Co., Ltd (HKPD), is a Micro Cap company, in the Pharmaceutical Retailers industry, last closed at $0.61, about 336.1% undervalued vs fair value, -44.0% 1Y return, ranked 687/1110 in sector.
$0.61
-4.98%
As of March 13, 2026
Previous close • Vol 90d: 67.5%
Market Cap
$7.04M
Enterprise Value
$8.67M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Hong Kong Pharma Digital Technology Holdings Ltd.

Top Beats
No strong beats yet

Quick Facts

Website https://www.9zt.hk
HQ Yau Tong
Employees 27
Fiscal year Mar 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$2
$3
$3
Current: $0.61 +336% vs base

Engine Room Money Flow™

Micro Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$20.3M
21.7%%
Gross Profit
$2.4M
-32.1%%
Operating Income
$200.8K
-88%%
Net Income
$-27.1K
-102%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
-1531.0%
Poor

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$927.3K
223.9% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
0/3
Improving
1
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Hong Kong Pharma Digital Technology Holdings Ltd's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
48
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
46
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 79% Coverage
Trade-Off Triangle Visualization A ternary plot showing HKPD's balance between Growth (33.7%), Profitability (32.3%), and Safety (34.0%). Growth 34% Safety 34% Profitability 32%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

64th percentile vs peers
64
Key Signals
Rev Growth YoY 21.7% 80p EPS Growth YoY 33.2% 40p
Strengths
  • Rev Growth Yoy in top 20% of peers (21.7%, 80th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Ebit Margin in top 20% of peers (0.7%, 80th percentile)
Risks

No significant risks identified for this axis.

Profitability

61th percentile vs peers
61
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

64th percentile vs peers
65
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Hong Kong Pharma Digital Technology Holdings Ltd.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$2.66
- - -
+336.1% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info